Elevance Health, Inc.
Intelligence Dossier
Elevance Health is a leading U.S. health insurer and integrated healthcare services company, offering commercial, Medicare, and Medicaid plans alongside pharmacy, behavioral, and clinical solutions.
-
Executive Summary: Elevance Health, Inc. (formerly Anthem, Inc.) is a Fortune 500 health benefits company that provides a spectrum of medical, digital, pharmacy, behavioral, and clinical services. It serves over 47 million medical members through affiliated Blue Cross and Blue Shield plans in 14 states and a broad portfolio of managed care solutions for government and commercial clients, aiming to be a lifetime, trusted health partner.
-
Government Reliance & Contracts: Elevance Health has significant reliance on federal and state government healthcare programs. Key contracts include:
- Medicaid Managed Care: Serves millions of low-income individuals and families through contracts with state Medicaid agencies across its Blue plan states.
- Medicare Advantage: Offers Medicare Advantage prescription drug plans and standalone Part D plans, with CMS reimbursement.
- Federal Employee Program (FEP): Administers the Blue Cross and Blue Shield Service Benefit Plan for federal employees, retirees, and their families, under contract with the U.S. Office of Personnel Management (OPM).
- Department of Defense: Provides TRICARE benefits as a subcontractor in certain regions. Overall, government-sponsored programs account for a substantial portion of its revenue (over 60% historically), making the company highly sensitive to policy changes and reimbursement rates.
- Moats & Key Technology:
- Regulatory & Brand Moat: Exclusive Blue Cross and Blue Shield licenses in 14 states, granting strong brand recognition, large provider networks, and high member retention.
- Scale & Data: Unmatched claims and clinical data from 100+ million members enable advanced analytics, risk stratification, and personalized care models.
- Technology Platforms: Carelon (its health services arm) integrates PBM (IngenioRx), behavioral health (Beacon), and complex care management, using AI-driven tools for care coordination, utilization management, and digital engagement. Investments in cloud-native platforms and interoperability drive efficiency and member experience.
- Patents: Holds numerous patents in predictive analytics, care navigation, and fraud detection (e.g., US patents for machine learning-based clinical decision support).
-
Capital & Shadow Backers: As a publicly traded company (NYSE: ELV), Elevance Health’s largest shareholders are institutional investors such as The Vanguard Group (approx. 9%), BlackRock (approx. 7%), and State Street. Originally part of the Blue Cross Blue Shield system, the company demutualized and went public as Anthem, Inc. in 2001. In 2022, it rebranded to Elevance Health to reflect its evolution beyond traditional insurance. There are no dominant private equity or venture capital backers.
-
Recent Catalysts:
- Medicaid Redeterminations: The unwinding of continuous enrollment post-COVID has led to membership losses in Medicaid, partly offset by growth in ACA marketplace and commercial segments.
- Carelon Expansion: Aggressive diversification into healthcare services (pharmacy, behavioral health, post-acute care) to generate higher-margin revenue and reduce cyclicality.
- Medicare Advantage Growth: Continued investment in MA plan benefits and star ratings, with expectations of long-term demographic tailwinds.
- Regulatory and Legislative Environment: Scrutiny of PBM practices, drug pricing reforms (Inflation Reduction Act), and MA payment rates are key watchpoints.
- Share Repurchases & Dividends: Strong capital return program underscores confidence in cash flow generation.
- Digital Health M&A: Acquired companies like myNEXUS (home health management) and Integra Managed Care to enhance post-acute capabilities, signaling a deeper push into value-based care.
Government Contracts & Awards
No recent government contracts or awards found.
Proprietary Tech & Patents
No patents found in our USPTO sample (a narrow, keyword-clustered feed of recent grants in strategic tech sectors — not a comprehensive patent database).
Form D Funding
No recent SEC Form D filings found.
Market Intelligence & News
No recent news or market intelligence found for this entity.
Congressional Trades in $ELV
Insider Trades (Form 4)
BOUDREAUX GAIL
Key People
BOUDREAUX GAIL
President and CEO
Political Giving
No disclosed PAC contributions found for this entity.
Factual Connections
Connections to other companies, executives, and politicians — sourced from disclosed trades, shared officers/directors, and public filings — are a Pro/Alpha feature.
Upgrade to Pro